Because human bone marrow ( BM ) CD34 + stem cells home into damaged tissue and may play an important role in tissue repair , this pilot clinical trial explored the safety and feasibility of intravitreal autologous CD34 + BM cells as potential therapy for ischemic or degenerative retinal conditions .